Cover Image
市場調查報告書

精神疾病治療用藥物:技術及全球市場

Drugs for Treating Mental Disorders: Technologies and Global Markets

出版商 BCC Research 商品編碼 208650
出版日期 內容資訊 英文 180 Pages
訂單完成後即時交付
價格
Back to Top
精神疾病治療用藥物:技術及全球市場 Drugs for Treating Mental Disorders: Technologies and Global Markets
出版日期: 2014年02月03日 內容資訊: 英文 180 Pages
簡介

全球精神疾病治療藥市場2012年為701億美元,預計2013年達689億美元。該市場2013-2018年間預計以2.3%的年複合成長率擴大,2018年達到771億美元的規模。

本報告提供全球精神疾病用治療藥市場相關調查分析、市場概要、世界市場趨勢分析、心理健康市場區隔的開發新藥、現有上市藥的資訊、及競爭環境的詳細分析等、參與企業簡介等彙整資料,為您概述為以下內容。

第1章 簡介

第2章 摘要

第3章 概要

  • 定義
  • 精神疾病的原因
  • 精神疾病的種類

第4章 法規情形

  • 新藥的認證
  • 新藥的申請
  • 回收、安全性的警告

第5章 得病率

  • 整體精神疾病
  • 憂鬱症
  • 焦慮症
  • 精神分裂症
  • 飲食障礙
  • 認知障礙
  • 睡眠障礙
  • 人格障礙
  • 酒精、藥物濫用
  • 兒童、青年精神障礙

第6章 新的發展

  • 憂鬱症
  • 焦慮症
  • 精神分裂症
  • 兒童、青年精神障礙
  • 認知障礙
  • 人格障礙
  • 飲食障礙
  • 藥物濫用
  • 睡眠障礙

第7章 市場分析

  • 憂鬱症、抗憂鬱劑市場

第8章 產業結構

  • 抗憂鬱劑
  • 抗精神病藥
  • 抗焦慮藥
  • 兒童、青年精神障礙
  • 躁鬱症
  • 認知障礙
  • 睡眠障礙
  • 藥物濫用治療藥

第9章 專利分析

  • 各年度
  • 各種類/分類
  • 各企業
  • 各國
  • 各申請者

第10章 企業簡介

第11章 附錄:簡稱

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHM074B

The global market for drugs used in mental disorders was $70.1 billion in 2012 and $68.9 billion in 2013. This market is expected to rise at a compound annual growth rate (CAGR) of 2.3% from 2013 to 2018 and reach $77.1 billion by 2018.

This report provides:

  • An overview of the market for drugs used to treat mental disorders.
  • Analyses of global market trends, with data from 2011 and 2012, estimates for 2013, and projections of CAGRs through 2018.
  • Information regarding new drug development in the mental health segment, existing products on the market, and a detailed analysis of the competitive environments.
  • An examination of current major market participants in the field, positive drivers and challenges, and other information affecting drug development.

REPORT SCOPE

INTRODUCTION

STUDY OBJECTIVES

The objective and tenacity in conducting this study is to provide an overview of the current and future characteristics of the global market for psychiatric drugs. The awareness and better understanding of mental disorders across the globe is on the rise. Globally, approximately 120 million people have been diagnosed with mental disorders and are taking psychiatric drugs as "treatment." The key objective is to present a comprehensive analysis and future direction of psychiatric drugs as a treatment for various mental disorders.

This report explores present and future strategies within the different classes of psychiatric drugs market, which includes antidepressants, antipsychotics, antianxiety (anxiolytics), childhood and adolescent mental disorders therapeutics, cognitive disorders therapeutics, sleep disorders therapeutics and substance abuse drugs. The growth of the market, the setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of medications in various mental disorders are discussed in this report.

A detailed analysis of the psychiatric drugs industry has been conducted. Revenues are broken down by the region and its types. Sales figures are estimated for the five-year period from 2013 through 2018.

The report also covers the prevalence of mental disorders, new developments in psychiatric drugs, regulatory aspects of these medications, and significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDY

The amount of mental illness medications have continued to grow over the past decade. There is a big increase in the use of powerful antipsychotic drugs across all ages in recent years. Wide research in the field of psychiatric drugs has revealed their ability to provide therapeutic treatments for various mental disorders. Pharmaceutical industries have now begun to explore the therapeutic use of psychiatric medications in their productions and processes. This has led to a continuous market for them.

R&D spending, along with increasing competition, patent expiries, new technologies and public awareness of mental disorders are directing this market. The advancements, new product launches and changing lifestyles have influenced the market to grow in the near future. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/ technology in light of the new technologies, growing competition and changing customer needs.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

This study contributes to the areas of market growth in psychiatric drug manufacturers and users. Pharmaceutical companies, research institutes and physicians will find this study to be of interest.

SCOPE OF THE STUDY

The scope of this study encompasses psychiatric drugs in pharmaceutical markets. BCC Research analyzes each market and its applications, regulatory environment, technology, market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes countries like India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand, etc.

Table of Contents

CHAPTER 1 INTRODUCTION 2

  • STUDY OBJECTIVES 2
  • REASONS FOR DOING THIS STUDY 2
  • CONTRIBUTIONS OF THE STUDY AND FOR WHOM 3
  • SCOPE OF THE STUDY 3
  • METHODOLOGY 3
  • INFORMATION SOURCES 3
  • ABOUT THE AUTHOR 3
  • RELATED BCC RESEARCH REPORTS 4
  • BCC RESEARCH ONLINE SERVICES 4
  • DISCLAIMER 5

CHAPTER 2 SUMMARY 7

  • SUMMARY TABLE GLOBAL REVENUE OF DRUGS USED IN MENTAL DISORDERS, THROUGH 2018 ($ MILLIONS) 8
  • SUMMARY FIGURE GLOBAL REVENUE OF DRUGS USED IN MENTAL DISORDERS, 2011-2018 ($ MILLIONS) 8

CHAPTER 3 OVERVIEW 10

  • DEFINITIONS 10
  • CAUSES OF MENTAL DISORDERS 10
    • BIOLOGICAL FACTORS 10
      • Genetics (Heredity) 11
      • Infections 11
      • Prenatal Damage 11
      • Substance Abuse 11
      • Other Factors 11
    • PSYCHOLOGICAL FACTORS 11
    • ENVIRONMENTAL FACTORS 12
  • TYPES OF MENTAL DISORDERS 12
    • DEPRESSION 12
      • Signs and Symptoms 12
      • Causes and Risk Factors 13
      • Forms of Depression 13
    • ANXIETY DISORDERS 14
      • Signs and Symptoms 14
      • Causes and Risk Factors 15
      • Forms of Anxiety Disorders 15
    • SCHIZOPHRENIA 17
      • Signs and Symptoms 17
      • Causes and Risk Factors 17
      • Forms of Schizophrenia 18
    • BIPOLAR DISORDER 18
      • Signs and Symptoms 19
      • Causes and Risk Factors 19
      • Types 19
    • EATING DISORDERS 20
      • Signs and Symptoms 20
      • Causes and Risk Factors 21
      • Types 21
    • COGNITIVE DISORDERS 21
      • Signs and Symptoms 22
      • Causes and Risk Factors 22
      • Forms 22
    • PERSONALITY DISORDERS 23
      • Signs and Symptoms 23
      • Causes and Risk Factors 24
      • Types of Personality Disorders 24
    • SLEEP DISORDERS 24
      • Signs and Symptoms 25
      • Causes and Risk Factors 25
      • Forms 25
        • Insomnia 25
        • Sleep Apnea 26
        • Narcolepsy 26
    • CHILDHOOD AND ADOLESCENT MENTAL DISORDERS 26
      • Attention-Deficit/Hyperactivity Disorder (ADHD) 26
        • Signs and Symptoms 26
        • Causes and Risk Factors 27
        • Forms of ADHD 27
      • Autism 27
        • Signs and Symptoms 27
          • Communication 28
          • Social Skills 28
          • Unusual Behaviors and Interests 28
        • Causes 28
        • Forms of Autism Spectrum Disorders 29
          • Autistic Disorder 29
          • Asperger's Syndrome 29
          • Pervasive Developmental Disorder (PDD) 29
          • Rett Syndrome 29
      • Childhood Disintegrative Disorder 29
    • SUBSTANCE AND ALCOHOL ABUSE AS MENTAL DISORDERS 29
      • Signs and Symptoms of Substance Abuse 30
      • Causes and Risk Factors 30
        • Biology 30
        • Environment 30
      • Forms 30
        • Tobacco Addiction 31
        • Alcohol 31
        • Cocaine 31
        • Heroin 31

CHAPTER 4 REGULATORY ASPECTS 33

  • NEW DRUG APPROVALS 33
  • TABLE 1 NEW DRUG APPROVALS FOR THE TREATMENT OF VARIOUS MENTAL DISORDERS, 2009 TO JULY 2013 33
  • NEW DRUG APPLICATIONS 37
  • TABLE 2 NEW DRUG APPLICATIONS, 2009 TO SEPTEMBER 2013 37
  • RECALLS AND SAFETY ALERTS 38
  • TABLE 3 RECALLS AND SAFETY ALERTS, 2009 TO SEPTEMBER 2013 39

CHAPTER 5 PREVALENCE 41

  • OVERALL MENTAL ILLNESS 41
  • TABLE 4 ANY MENTAL ILLNESS AMONG U.S. PEOPLE AGE 18 YEARS OR OLDER, 2010 AND 2011 (THOUSANDS) 42
  • FIGURE 1 ANY MENTAL ILLNESS AMONG U.S. PEOPLE AGE 18 YEARS OR OLDER, 2010 AND 2011 (THOUSANDS) 42
  • TABLE 5 SERIOUS MENTAL ILLNESS AMONG U.S. PEOPLE AGE 18 YEARS OR OLDER, 2010 AND 2011 (THOUSANDS) 43
  • FIGURE 2 SERIOUS MENTAL ILLNESS AMONG U.S. PEOPLE AGE 18 YEARS OR OLDER, 2010 AND 2011 (THOUSANDS) 43
  • TABLE 6 NUMBER OF CASES AFFECTED BY MENTAL DISORDERS IN EUROPE, 2011 (MILLIONS/%) 44
  • FIGURE 3 NUMBER OF CASES AFFECTED BY MENTAL DISORDERS IN EUROPE, 2011 (MILLIONS/%) 44
  • DEPRESSION 44
  • ANXIETY DISORDERS 45
  • SCHIZOPHRENIA 45
  • EATING DISORDERS 45
  • COGNITIVE DISORDERS 46
  • SLEEP DISORDER 46
  • TABLE 7 NUMBER OF CASES AFFECTED BY OBSTRUCTIVE SLEEP APNEA (OSA) IN VARIOUS COUNTRIES (%/MILLIONS) 46
  • FIGURE 4 NUMBER OF CASES AFFECTED BY OBSTRUCTIVE SLEEP APNEA (OSA) IN VARIOUS COUNTRIES (%/MILLIONS) 47
  • PERSONALITY DISORDER 47
  • ALCOHOL AND SUBSTANCE ABUSE 47
  • CHILDHOOD AND ADOLESCENT MENTAL DISORDERS 48

CHAPTER 6 NEW DEVELOPMENTS 50

  • DEPRESSION 50
  • TABLE 8 NEW DEVELOPMENTS IN DEPRESSION 51
  • ANXIETY 53
  • TABLE 9 NEW DEVELOPMENTS IN ANXIETY 53
  • SCHIZOPHRENIA 54
  • TABLE 10 NEW DEVELOPMENTS IN SCHIZOPHRENIA 54
  • CHILDHOOD AND ADOLESCENT MENTAL DISORDERS 55
  • TABLE 11 NEW DEVELOPMENTS IN CHILDHOOD AND ADOLESCENT MENTAL
  • DISORDERS 56
  • COGNITIVE DISORDERS 57
  • TABLE 12 NEW DEVELOPMENTS IN COGNITIVE DISORDERS 57
  • PERSONALITY DISORDERS 58
  • TABLE 13 NEW DEVELOPMENTS IN PERSONALITY DISORDERS 58
  • EATING DISORDERS 58
  • TABLE 14 NEW DEVELOPMENTS IN EATING DISORDERS 59
  • SUBSTANCE ABUSE 59
  • TABLE 15 NEW DEVELOPMENTS IN SUBSTANCE ABUSE 60
  • SLEEP DISORDER 60
  • TABLE 16 NEW DEVELOPMENTS IN SLEEP DISORDERS 60

CHAPTER 7 MARKET ANALYSIS 63

  • DEPRESSION AND ANTIDEPRESSANTS DRUG MARKET 63
    • MARKET BY REGION 64
      • Market Overview 64
      • Market Revenue 65
      • TABLE 17 GLOBAL MARKET REVENUE OF ANTIDEPRESSANTS BY REGION, THROUGH 2018 ($ MILLIONS) 65
      • FIGURE 5 GLOBAL MARKET REVENUE OF ANTIDEPRESSANTS BY REGION, 2011-2018 ($ MILLIONS) 65
      • Market Share 66
      • TABLE 18 MARKET SHARE OF ANTIDEPRESSANTS BY REGION, 2012 (%) 66
      • FIGURE 6 MARKET SHARE OF ANTIDEPRESSANTS BY REGION, 2012 (%) 66
    • MARKET BY TYPE 66
      • Market Overview 67
      • Market Revenue 68
      • TABLE 19 GLOBAL MARKET REVENUE OF ANTIDEPRESSANTS BY TYPE, THROUGH 2018 ($ MILLIONS) 68
      • FIGURE 7 GLOBAL MARKET REVENUE OF ANTIDEPRESSANTS BY TYPE, 2011-2018 ($ MILLIONS) 68
      • ANTIPSYCHOTICS MARKET 69
    • MARKET BY REGION 69
      • Market Overview 69
      • Market Revenue 70
      • TABLE 20 GLOBAL MARKET REVENUE OF ANTIPSYCHOTICS BY REGION, THROUGH 2018 ($ MILLIONS) 71
      • FIGURE 8 GLOBAL MARKET REVENUE OF ANTIPSYCHOTICS BY REGION, 2011-2018 ($ MILLIONS) 71
      • Market Share 71
      • TABLE 21 MARKET SHARE OF ANTIPSYCHOTICS BY REGION, 2012 (%) 72
      • FIGURE 9 MARKET SHARE OF ANTIPSYCHOTICS BY REGION, 2012 (%) 72
    • MARKET BY TYPE 72
      • Market Overview 73
      • Market Revenue 74
      • TABLE 22 GLOBAL MARKET REVENUE OF ANTIPSYCHOTICS BY TYPE, THROUGH 2018 ($ MILLIONS) 74
      • FIGURE 10 GLOBAL MARKET REVENUE OF ANTIPSYCHOTICS BY TYPE, 2011-2018 ($ MILLIONS) 74
      • ANXIETY DISORDERS AND ANXIOLYTICS MARKET 75
    • MARKET BY REGION 75
      • Market Overview 75
      • Market Revenue 75
      • TABLE 23 MARKET REVENUE OF ANXIOLYTIC DRUGS BY REGION, THROUGH 2018 ($ MILLIONS) 76
      • FIGURE 11 MARKET REVENUE OF ANXIOLYTIC DRUGS BY REGION, 2011-2018 ($ MILLIONS) 76
      • Market Share 76
      • TABLE 24 MARKET SHARE OF ANXIOLYTICS BY REGION, 2012 (%) 77
      • FIGURE 12 MARKET SHARE OF ANXIOLYTICS BY REGION, 2012 (%) 77
    • MARKET BY TYPE 77
      • Market Overview 77
      • Market Revenue 78
      • TABLE 25 MARKET REVENUE OF ANTIANXIETY DRUGS BY TYPE, THROUGH 2018 ($ MILLIONS) 78
      • FIGURE 13 MARKET REVENUE OF ANTIANXIETY DRUGS BY TYPE, 2011-2018 ($ MILLIONS) 79
      • SCHIZOPHRENIA MEDICATION MARKET 79
    • MARKET BY REGION 79
      • Market Overview 79
      • Market Revenue 80
      • TABLE 26 MARKET REVENUE OF DRUGS USED IN SCHIZOPHRENIA BY REGION, THROUGH 2018 ($ MILLIONS) 81
      • FIGURE 14 MARKET REVENUE OF DRUGS USED IN SCHIZOPHRENIA BY REGION, 2011-2018 ($ MILLIONS) 81
      • Market Share 82
      • TABLE 27 MARKET SHARE OF DRUGS USED IN SCHIZOPHRENIA BY REGION, 2012 (%) 82
      • FIGURE 15 MARKET SHARE OF DRUGS USED IN SCHIZOPHRENIA BY REGION, 2012 (%) 82
    • MARKET BY TYPE 82
      • Market Overview 83
      • Market Revenue 84
      • TABLE 28 MARKET REVENUE OF SCHIZOPHRENIC DRUGS BY TYPE, THROUGH 2018 ($ MILLIONS) 84
      • FIGURE 16 MARKET REVENUE OF SCHIZOPHRENIC DRUGS BY TYPE, 2011-2018 ($ MILLIONS) 85
      • BIPOLAR DISORDERS MARKET 85
    • MARKET BY REGION 85
      • Market Overview 86
      • Market Revenue 86
      • TABLE 29 MARKET REVENUE FOR BIPOLAR DISORDER DRUGS BY REGION, THROUGH 2018 ($ MILLIONS) 87
      • FIGURE 17 MARKET REVENUE FOR BIPOLAR DISORDER DRUGS BY REGION, 2011-2018 ($ MILLIONS) 87
      • Market Share 88
      • TABLE 30 MARKET SHARE OF BIPOLAR DISORDER DRUGS BY REGION, 2012 (%) 88
      • FIGURE 18 MARKET SHARE OF BIPOLAR DISORDER DRUGS BY REGION, 2012 (%) 88
    • MARKET BY TYPE 88
      • Market Overview 89
      • Market Revenue 89
      • TABLE 31 MARKET REVENUE OF BIPOLAR DISORDER DRUGS BY TYPE, THROUGH 2018 ($ MILLIONS) 90
      • FIGURE 19 MARKET REVENUE OF BIPOLAR DISORDER DRUGS BY TYPE, 2011-2018 ($ MILLIONS) 90
      • CHILDHOOD AND ADOLESCENT MENTAL DISORDERS MARKET 90
    • MARKET BY REGION 91
      • Market Overview 91
      • Market Revenue 92
      • TABLE 32 MARKET REVENUE FOR CHILDHOOD AND ADOLESCENT MENTAL
      • DISORDERS DRUGS BY REGION, THROUGH 2018 ($ MILLIONS) 93
      • FIGURE 20 MARKET REVENUE FOR CHILDHOOD AND ADOLESCENT MENTAL
      • DISORDERS DRUGS BY REGION, 2011-2018 ($ MILLIONS) 94
      • Market Share 94
      • TABLE 33 MARKET SHARE OF CHILDHOOD AND ADOLESCENT DISORDERS DRUGS
      • BY REGION, 2012 (%) 94
      • FIGURE 21 MARKET SHARE OF CHILDHOOD AND ADOLESCENT DISORDERS DRUGS
      • BY REGION, 2012 (%) 94
    • MARKET BY TYPE 95
      • Market Overview 95
      • Market Revenue 96
      • TABLE 34 MARKET REVENUE OF CHILDHOOD AND ADOLESCENT MENTAL
      • DISORDERS DRUGS BY TYPE, THROUGH 2018 ($ MILLIONS) 97
      • FIGURE 22 MARKET REVENUE OF CHILDHOOD AND ADOLESCENT MENTAL
      • DISORDERS DRUGS BY TYPE, 2011-2018 ($ MILLIONS) 97
      • EATING DISORDER DRUGS MARKET 97
      • COGNITIVE DISORDERS DRUGS MARKET 98
    • MARKET BY REGION 99
      • Market Overview 99
      • Market Revenue 100
      • TABLE 35 MARKET REVENUE FOR COGNITIVE DISORDERS DRUGS BY REGION,
      • THROUGH 2018 ($ MILLIONS) 100
      • FIGURE 23 MARKET REVENUE FOR COGNITIVE DISORDERS DRUGS BY REGION,
      • 2011-2018 ($ MILLIONS) 100
      • Market Share 101
      • TABLE 36 MARKET SHARE OF COGNITIVE DISORDERS DRUGS BY REGION, 2012 (%) 101
      • FIGURE 24 MARKET SHARE OF COGNITIVE DISORDERS DRUGS BY REGION, 2012
      • (%) 101
    • MARKET BY TYPE 102
      • Market Overview 103
      • Market Revenue 103
      • TABLE 37 MARKET REVENUE OF COGNITIVE DISORDERS DRUGS BY TYPE,
      • THROUGH 2018 ($ MILLIONS) 104
      • FIGURE 25 MARKET REVENUE OF COGNITIVE DISORDERS DRUGS BY TYPE,
      • 2011-2018 ($ MILLIONS) 104
      • SUBSTANCE AND ALCOHOL ADDICTIONS AS MENTAL HEALTH DISORDERS 104
    • MARKET BY REGION 105
      • Market Overview 105
      • Market Revenue 106
      • TABLE 38 MARKET REVENUE OF SUBSTANCE AND ALCOHOL ADDICTION DRUG PRODUCTS BY REGION, THROUGH 2018 ($ MILLIONS) 106
      • FIGURE 26 MARKET REVENUE OF SUBSTANCE AND ALCOHOL ADDICTION DRUG PRODUCTS BY REGION, 2011-2018 ($ MILLIONS) 106
      • Market Share 107
      • TABLE 39 MARKET SHARE OF SUBSTANCE ABUSE DRUGS BY REGION, 2012 (%) 107
      • FIGURE 27 MARKET SHARE OF SUBSTANCE ABUSE DRUGS BY REGION, 2012 (%) 107
    • MARKET BY TYPE 108
      • Market Overview 108
      • Market Revenue 109
      • TABLE 40 MARKET REVENUE OF DRUGS USED IN SUBSTANCE AND ALCOHOL ADDICTIONS BY TYPE, THROUGH 2018 ($ MILLIONS) 110
      • FIGURE 28 MARKET REVENUE OF DRUGS USED IN SUBSTANCE AND ALCOHOL ADDICTIONS BY TYPE, 2011-2018 ($ MILLIONS) 110
      • SLEEP DISORDERS AS MENTAL HEALTH CONDITIONS 111
    • MARKET BY REGION 111
      • Market Overview 111
      • Market Revenue 112
      • TABLE 41 MARKET REVENUE FOR SLEEP DISORDER DRUGS BY REGION, THROUGH 2018 ($ MILLIONS) 112
      • FIGURE 29 MARKET REVENUE FOR SLEEP DISORDER DRUGS BY REGION, 2011-2018 ($ MILLIONS) 112
      • Market Share 113
      • TABLE 42 MARKET SHARE OF SLEEP DISORDERS THERAPEUTICS BY REGION, 2012 (%) 113
      • FIGURE 30 MARKET SHARE OF SLEEP DISORDERS THERAPEUTICS BY REGION, 2012 (%) 113
    • MARKET BY TYPE 113
      • Market Overview 114
      • Market Revenue 114
      • TABLE 43 MARKET REVENUE OF DRUGS USED IN SLEEP DISORDERS BY TYPE, THROUGH 2018 ($ MILLIONS) 115
      • FIGURE 31 MARKET REVENUE OF DRUGS USED IN SLEEP DISORDERS BY TYPE, 2011-2018 ($ MILLIONS) 115
      • PERSONALITY DISORDERS MARKET 116
      • DRUGS USED FOR OTHER MENTAL DISORDERS 116

CHAPTER 8 INDUSTRY STRUCTURE 120

  • ANTIDEPRESSANTS 120
    • MARKET LEADERS 120
    • TABLE 44 GLOBAL MANUFACTURERS OF ANTIDEPRESSANTS, 2012 120
    • MARKET SHARE 124
    • TABLE 45 MARKET SHARE OF ANTIDEPRESSANT DRUG MANUFACTURING COMPANIES, 2012 (%) 125
    • FIGURE 32 MARKET SHARE OF ANTIDEPRESSANT DRUG MANUFACTURING COMPANIES, 2012 (%) 125
  • ANTIPSYCHOTICS 125
    • MARKET LEADERS 125
    • TABLE 46 GLOBAL MANUFACTURERS OF ANTIPSYCHOTICS, 2012 126
    • MARKET SHARE 127
    • TABLE 47 MARKET SHARE OF ANTIPSYCHOTIC DRUGS MANUFACTURING COMPANIES, 2012 (%) 127
    • FIGURE 33 MARKET SHARE OF ANTIPSYCHOTIC DRUG MANUFACTURING COMPANIES, 2012 (%) 128
  • ANTIANXIETY DRUGS 128
    • MARKET LEADERS 128
    • TABLE 48 GLOBAL MANUFACTURERS OF DRUGS TO TREAT ANXIETY, 2012 128
    • MARKET SHARE 131
    • TABLE 49 MARKET SHARE OF ANTIANXIETY DRUG MANUFACTURING COMPANIES, 2012 (%) 131
    • FIGURE 34 MARKET SHARE OF ANTIANXIETY DRUG MANUFACTURING COMPANIES, 2012 (%) 131
  • CHILDHOOD AND ADOLESCENT MENTAL DISORDERS 132
    • MARKET LEADERS 132
    • TABLE 50 GLOBAL MANUFACTURERS OF DRUGS TO TREAT CHILDHOOD AND ADOLESCENT MENTAL DISORDERS, 2012 132
    • MARKET SHARE 133
    • TABLE 51 MARKET SHARE OF CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUG MANUFACTURING COMPANIES, 2012 (%) 133
    • FIGURE 35 MARKET SHARE OF CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUG MANUFACTURING COMPANIES, 2012 (%) 134
  • BIPOLAR DISORDERS 134
    • MARKET LEADERS 134
    • TABLE 52 GLOBAL MANUFACTURERS OF DRUGS TO TREAT BIPOLAR DISORDER, 2012 134
    • MARKET SHARE 137
    • TABLE 53 MARKET SHARE OF BIPOLAR DISORDER DRUG MANUFACTURING COMPANIES, 2012 (%) 138
    • FIGURE 36 MARKET SHARE OF BIPOLAR DISORDER DRUG MANUFACTURING COMPANIES, 2012 (%) 138
  • COGNITIVE DISORDERS 139
    • MARKET LEADERS 139
    • TABLE 54 GLOBAL MANUFACTURERS OF DRUGS TO TREAT COGNITIVE DISORDERS, 2012 139
    • MARKET SHARE 140
    • TABLE 55 MARKET SHARE OF COGNITIVE DISORDER DRUG MANUFACTURING COMPANIES, 2012 (%) 140
    • FIGURE 37 MARKET SHARE OF COGNITIVE DISORDERS DRUG MANUFACTURING COMPANIES, 2012 (%) 140
  • SLEEP DISORDERS 141
    • MARKET LEADERS 141
    • TABLE 56 GLOBAL MANUFACTURERS OF DRUGS TO TREAT SLEEP DISORDERS, 2012 141
    • MARKET SHARE 142
    • TABLE 57 MARKET SHARE OF SLEEP DISORDER DRUGS MANUFACTURING COMPANIES, 2012 (%) 143
    • FIGURE 38 MARKET SHARE OF SLEEP DISORDERS DRUG MANUFACTURING COMPANIES, 2012 (%) 143
  • SUBSTANCE ABUSE DRUGS 144
    • MARKET LEADERS 144
    • TABLE 58 GLOBAL MANUFACTURERS OF DRUGS TO TREAT SUBSTANCE ABUSE, 2012 144
    • MARKET SHARE 145
    • TABLE 59 MARKET SHARE OF SUBSTANCE ABUSE DRUG MANUFACTURING COMPANIES, 2012 (%) 146
    • FIGURE 39 MARKET SHARE OF SUBSTANCE ABUSE DRUG MANUFACTURING COMPANIES, 2012 (%) 146

CHAPTER 9 PATENT ANALYSIS 148

  • PATENTS BY YEAR 148
  • TABLE 60 NUMBER OF SIGNIFICANT PATENTS BY YEAR, JANUARY 2009 TO SEPTEMBER 2013 148
  • FIGURE 40 NUMBER OF SIGNIFICANT PATENTS BY YEAR, JANUARY 2009 TO SEPTEMBER 2013 148
  • PATENTS BY TYPE/CATEGORY 149
  • TABLE 61 PATENTS BY CATEGORY, JANUARY 2009 TO SEPTEMBER 2013 149
  • FIGURE 41 PATENTS BY CATEGORY, JANUARY 2009 TO SEPTEMBER 2013 150
  • PATENTS BY COMPANY 150
  • TABLE 62 NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009 TO JUNE 2013 151
  • PATENTS BY COUNTRY 153
  • TABLE 63 NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009 TO SEPTEMBER 2013 153
  • TABLE 64 PATENT SHARES BY COUNTRY, JANUARY 2009 TO SEPTEMBER 2013 (%) 154
  • FIGURE 42 PATENT SHARES BY COUNTRY, JANUARY 2009 TO SEPTEMBER 2013 (%) 155
  • PATENTS BY ASSIGNEE 155
  • TABLE 65 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009 TO JUNE 2013 155
  • FIGURE 43 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009 TO JUNE 2013 155

CHAPTER 10 COMPANY PROFILES 158

  • ABBVIE INC 158
  • ACTAVIS PLC 158
  • ALEMBIC PHARMACEUTICALS LTD. 159
  • ALKERMES PLC 159
  • AMEDRA PHARMCEUTICALS 160
  • ANGELINI PHARMA 160
  • APOTEX PHARMACHEM 161
  • ASTRAZENECA 161
  • BOEHRINGER INGELHEIM 162
  • BRISTOL-MYERS SQUIBB 162
  • CIPLA 163
  • COVIS PHARMA 163
  • CYPRESS BIOSCIENCE 164
  • DR. REDDY'S LABORATORIES 164
  • EDGEMONT PHARMS LLC 165
  • EISAI INC 165
  • ELI LILLY & COMPANY 166
  • FOREST LABS 167
  • FOUGERA PHARMACEUTICALS INC. 167
  • FRESENIUS KABI USA 167
  • GLAXOSMITHKLINE 168
  • GLENMARK PHARMACEUTICALS 168
  • HOFFMAN-LA-ROCHE 169
  • HOSPIRA 169
  • JANSSEN-CILAG 170
  • JOHNSON & JOHNSON 170
  • JAZZ PHARMACEUTICALS 171
  • LUNDBECK LLC 172
  • LUPIN PHARMACEUTICALS INC. 172
  • MALLINCKRODT PHARMACEUTICALS 172
  • MERCK AND CO. 173
  • MYLAN INC. 174
  • NOVARTIS 174
  • NOVEL LABS INC. 175
  • NOVEN PHARMACEUTICALS INC. 175
  • OREXO AB 176
  • OSMOTICA PHARMACEUTICAL CORP. 176
  • OTSUKA AMERICA PHARMACEUTICAL INC. 177
  • PAR PHARMACEUTICAL COMPANIES INC. 177
  • PERNIX THERAPEUTICS 178
  • PFIZER INC. 178
  • PURDUE PHARMA LP 179
  • RANBAXY 180
  • RECKITT BENCKISER 180
  • ROXANE LABORATORIES LTD. 181
  • SANDOZ INTERNATIONAL GMBH 181
  • SANOFI 182
  • SHIRE 183
  • SUN PHARMA GLOBAL 183
  • SUNOVION PHARMS INC 184
  • TAKEDA PHARMACEUTICALS 184
  • TARO PHARMACEUTICAL INDUSTRIES 185
  • TEVA PHARMACEUTICAL INDUSTRIES LTD. 185
  • TORRENT PHARMACEUTICALS LIMITED 186
  • UCB COMPANY 186
  • UNICHEM LABORATORIES LIMITED 187
  • VALEANT PHARMACEUTICAL INTERNATIONAL INC 187
  • VALIDUS PHARMACEUTICALS LLC 187
  • WATSON LABS 188
  • WOCKHARDT LIMITED 188
  • ZYDUS PHARMACEUTICALS INC 189

CHAPTER 11 APPENDIX-ABBREVIATIONS 191

LIST OF TABLES

  • SUMMARY TABLE GLOBAL REVENUE OF DRUGS USED IN MENTAL DISORDERS, THROUGH 2018 ($ MILLIONS) 8
  • TABLE 1 NEW DRUG APPROVALS FOR THE TREATMENT OF VARIOUS MENTAL DISORDERS, 2009 TO JULY 2013 33
  • TABLE 2 NEW DRUG APPLICATIONS, 2009 TO SEPTEMBER 2013 37
  • TABLE 3 RECALLS AND SAFETY ALERTS, 2009 TO SEPTEMBER 2013 39
  • TABLE 4 ANY MENTAL ILLNESS AMONG U.S. PEOPLE AGE 18 YEARS OR OLDER, 2010 AND 2011 (THOUSANDS) 42
  • TABLE 5 SERIOUS MENTAL ILLNESS AMONG U.S. PEOPLE AGE 18 YEARS OR OLDER, 2010 AND 2011 (THOUSANDS) 43
  • TABLE 6 NUMBER OF CASES AFFECTED BY MENTAL DISORDERS IN EUROPE, 2011 (MILLIONS/%) 44
  • TABLE 7 NUMBER OF CASES AFFECTED BY OBSTRUCTIVE SLEEP APNEA (OSA) IN VARIOUS COUNTRIES (%/MILLIONS) 46
  • TABLE 8 NEW DEVELOPMENTS IN DEPRESSION 51
  • TABLE 9 NEW DEVELOPMENTS IN ANXIETY 53
  • TABLE 10 NEW DEVELOPMENTS IN SCHIZOPHRENIA 54
  • TABLE 11 NEW DEVELOPMENTS IN CHILDHOOD AND ADOLESCENT MENTAL DISORDERS 56
  • TABLE 12 NEW DEVELOPMENTS IN COGNITIVE DISORDERS 57
  • TABLE 13 NEW DEVELOPMENTS IN PERSONALITY DISORDERS 58
  • TABLE 14 NEW DEVELOPMENTS IN EATING DISORDERS 59
  • TABLE 15 NEW DEVELOPMENTS IN SUBSTANCE ABUSE 60
  • TABLE 16 NEW DEVELOPMENTS IN SLEEP DISORDERS 60
  • TABLE 17 GLOBAL MARKET REVENUE OF ANTIDEPRESSANTS BY REGION, THROUGH 2018 ($ MILLIONS) 65
  • TABLE 18 MARKET SHARE OF ANTIDEPRESSANTS BY REGION, 2012 (%) 66
  • TABLE 19 GLOBAL MARKET REVENUE OF ANTIDEPRESSANTS BY TYPE, THROUGH 2018 ($ MILLIONS) 68
  • TABLE 20 GLOBAL MARKET REVENUE OF ANTIPSYCHOTICS BY REGION, THROUGH 2018 ($ MILLIONS) 71
  • TABLE 21 MARKET SHARE OF ANTIPSYCHOTICS BY REGION, 2012 (%) 72
  • TABLE 22 GLOBAL MARKET REVENUE OF ANTIPSYCHOTICS BY TYPE, THROUGH 2018 ($ MILLIONS) 74
  • TABLE 23 MARKET REVENUE OF ANXIOLYTIC DRUGS BY REGION, THROUGH 2018 ($ MILLIONS) 76
  • TABLE 24 MARKET SHARE OF ANXIOLYTICS BY REGION, 2012 (%) 77
  • TABLE 25 MARKET REVENUE OF ANTIANXIETY DRUGS BY TYPE, THROUGH 2018 ($ MILLIONS) 78
  • TABLE 26 MARKET REVENUE OF DRUGS USED IN SCHIZOPHRENIA BY REGION, THROUGH 2018 ($ MILLIONS) 81
  • TABLE 27 MARKET SHARE OF DRUGS USED IN SCHIZOPHRENIA BY REGION, 2012 (%) 82
  • TABLE 28 MARKET REVENUE OF SCHIZOPHRENIC DRUGS BY TYPE, THROUGH 2018 ($ MILLIONS) 84
  • TABLE 29 MARKET REVENUE FOR BIPOLAR DISORDER DRUGS BY REGION, THROUGH 2018 ($ MILLIONS) 87
  • TABLE 30 MARKET SHARE OF BIPOLAR DISORDER DRUGS BY REGION, 2012 (%) 88
  • TABLE 31 MARKET REVENUE OF BIPOLAR DISORDER DRUGS BY TYPE, THROUGH 2018 ($ MILLIONS) 90
  • TABLE 32 MARKET REVENUE FOR CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUGS BY REGION, THROUGH 2018 ($ MILLIONS) 93
  • TABLE 33 MARKET SHARE OF CHILDHOOD AND ADOLESCENT DISORDERS DRUGS BYREGION, 2012 (%) 94
  • TABLE 34 MARKET REVENUE OF CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUGS BY TYPE, THROUGH 2018 ($ MILLIONS) 97
  • TABLE 35 MARKET REVENUE FOR COGNITIVE DISORDERS DRUGS BY REGION, THROUGH 2018 ($ MILLIONS) 100
  • TABLE 36 MARKET SHARE OF COGNITIVE DISORDERS DRUGS BY REGION, 2012 (%) 101
  • TABLE 37 MARKET REVENUE OF COGNITIVE DISORDERS DRUGS BY TYPE, THROUGH 2018 ($ MILLIONS) 104
  • TABLE 38 MARKET REVENUE OF SUBSTANCE AND ALCOHOL ADDICTION DRUG PRODUCTS BY REGION, THROUGH 2018 ($ MILLIONS) 106
  • TABLE 39 MARKET SHARE OF SUBSTANCE ABUSE DRUGS BY REGION, 2012 (%) 107
  • TABLE 40 MARKET REVENUE OF DRUGS USED IN SUBSTANCE AND ALCOHOL ADDICTIONS BY TYPE, THROUGH 2018 ($ MILLIONS) 110
  • TABLE 41 MARKET REVENUE FOR SLEEP DISORDER DRUGS BY REGION, THROUGH 2018 ($ MILLIONS) 112
  • TABLE 42 MARKET SHARE OF SLEEP DISORDERS THERAPEUTICS BY REGION, 2012 (%) 113
  • TABLE 43 MARKET REVENUE OF DRUGS USED IN SLEEP DISORDERS BY TYPE, THROUGH 2018 ($ MILLIONS) 115
  • TABLE 44 GLOBAL MANUFACTURERS OF ANTIDEPRESSANTS, 2012 120
  • TABLE 45 MARKET SHARE OF ANTIDEPRESSANT DRUG MANUFACTURING COMPANIES, 2012 (%) 125
  • TABLE 46 GLOBAL MANUFACTURERS OF ANTIPSYCHOTICS, 2012 126
  • TABLE 47 MARKET SHARE OF ANTIPSYCHOTIC DRUGS MANUFACTURING COMPANIES, 2012 (%) 127
  • TABLE 48 GLOBAL MANUFACTURERS OF DRUGS TO TREAT ANXIETY, 2012 128
  • TABLE 49 MARKET SHARE OF ANTIANXIETY DRUG MANUFACTURING COMPANIES, 2012 (%) 131
  • TABLE 50 GLOBAL MANUFACTURERS OF DRUGS TO TREAT CHILDHOOD AND ADOLESCENT MENTAL DISORDERS, 2012 132
  • TABLE 51 MARKET SHARE OF CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUG MANUFACTURING COMPANIES, 2012 (%) 133
  • TABLE 52 GLOBAL MANUFACTURERS OF DRUGS TO TREAT BIPOLAR DISORDER, 2012 134
  • TABLE 53 MARKET SHARE OF BIPOLAR DISORDER DRUG MANUFACTURING COMPANIES, 2012 (%) 138
  • TABLE 54 GLOBAL MANUFACTURERS OF DRUGS TO TREAT COGNITIVE DISORDERS, 2012 139
  • TABLE 55 MARKET SHARE OF COGNITIVE DISORDER DRUG MANUFACTURING COMPANIES, 2012 (%) 140
  • TABLE 56 GLOBAL MANUFACTURERS OF DRUGS TO TREAT SLEEP DISORDERS, 2012 141
  • TABLE 57 MARKET SHARE OF SLEEP DISORDER DRUGS MANUFACTURING COMPANIES, 2012 (%) 143
  • TABLE 58 GLOBAL MANUFACTURERS OF DRUGS TO TREAT SUBSTANCE ABUSE, 2012 144
  • TABLE 59 MARKET SHARE OF SUBSTANCE ABUSE DRUG MANUFACTURING COMPANIES, 2012 (%) 146
  • TABLE 60 NUMBER OF SIGNIFICANT PATENTS BY YEAR, JANUARY 2009 TO SEPTEMBER 2013 148
  • TABLE 61 PATENTS BY CATEGORY, JANUARY 2009 TO SEPTEMBER 2013 149
  • TABLE 62 NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009 TO JUNE 2013 151
  • TABLE 63 NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009 TO SEPTEMBER 2013 153
  • TABLE 64 PATENT SHARES BY COUNTRY, JANUARY 2009 TO SEPTEMBER 2013 (%) 154
  • TABLE 65 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009 TO JUNE 2013 155

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL REVENUE OF DRUGS USED IN MENTAL DISORDERS, 2011-2018 ($ MILLIONS) 8
  • FIGURE 1 ANY MENTAL ILLNESS AMONG U.S. PEOPLE AGE 18 YEARS OR OLDER, 2010 AND 2011 (THOUSANDS) 42
  • FIGURE 2 SERIOUS MENTAL ILLNESS AMONG U.S. PEOPLE AGE 18 YEARS OR OLDER, 2010 AND 2011 (THOUSANDS) 43
  • FIGURE 3 NUMBER OF CASES AFFECTED BY MENTAL DISORDERS IN EUROPE, 2011 (MILLIONS/%) 44
  • FIGURE 4 NUMBER OF CASES AFFECTED BY OBSTRUCTIVE SLEEP APNEA (OSA) IN VARIOUS COUNTRIES (%/MILLIONS) 47
  • FIGURE 5 GLOBAL MARKET REVENUE OF ANTIDEPRESSANTS BY REGION, 2011-2018 ($ MILLIONS) 65
  • FIGURE 6 MARKET SHARE OF ANTIDEPRESSANTS BY REGION, 2012 (%) 66
  • FIGURE 7 GLOBAL MARKET REVENUE OF ANTIDEPRESSANTS BY TYPE, 2011-2018 ($ MILLIONS) 68
  • FIGURE 8 GLOBAL MARKET REVENUE OF ANTIPSYCHOTICS BY REGION, 2011-2018 ($ MILLIONS) 71
  • FIGURE 9 MARKET SHARE OF ANTIPSYCHOTICS BY REGION, 2012 (%) 72
  • FIGURE 10 GLOBAL MARKET REVENUE OF ANTIPSYCHOTICS BY TYPE, 2011-2018 ($ MILLIONS) 74
  • FIGURE 11 MARKET REVENUE OF ANXIOLYTIC DRUGS BY REGION, 2011-2018 ($ MILLIONS) 76
  • FIGURE 12 MARKET SHARE OF ANXIOLYTICS BY REGION, 2012 (%) 77
  • FIGURE 13 MARKET REVENUE OF ANTIANXIETY DRUGS BY TYPE, 2011-2018 ($ MILLIONS) 79
  • FIGURE 14 MARKET REVENUE OF DRUGS USED IN SCHIZOPHRENIA BY REGION, 2011-2018 ($ MILLIONS) 81
  • FIGURE 15 MARKET SHARE OF DRUGS USED IN SCHIZOPHRENIA BY REGION, 2012 (%) 82
  • FIGURE 16 MARKET REVENUE OF SCHIZOPHRENIC DRUGS BY TYPE, 2011-2018 ($ MILLIONS) 85
  • FIGURE 17 MARKET REVENUE FOR BIPOLAR DISORDER DRUGS BY REGION, 2011-2018 ($ MILLIONS) 87
  • FIGURE 18 MARKET SHARE OF BIPOLAR DISORDER DRUGS BY REGION, 2012 (%) 88
  • FIGURE 19 MARKET REVENUE OF BIPOLAR DISORDER DRUGS BY TYPE, 2011-2018 ($ MILLIONS) 90
  • FIGURE 20 MARKET REVENUE FOR CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUGS BY REGION, 2011-2018 ($ MILLIONS) 94
  • FIGURE 21 MARKET SHARE OF CHILDHOOD AND ADOLESCENT DISORDERS DRUGS BY REGION, 2012 (%) 94
  • FIGURE 22 MARKET REVENUE OF CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUGS BY TYPE, 2011-2018 ($ MILLIONS) 97
  • FIGURE 23 MARKET REVENUE FOR COGNITIVE DISORDERS DRUGS BY REGION, 2011-2018 ($ MILLIONS) 100
  • FIGURE 24 MARKET SHARE OF COGNITIVE DISORDERS DRUGS BY REGION, 2012 (%) 101
  • FIGURE 25 MARKET REVENUE OF COGNITIVE DISORDERS DRUGS BY TYPE, 2011-2018 ($ MILLIONS) 104
  • FIGURE 26 MARKET REVENUE OF SUBSTANCE AND ALCOHOL ADDICTION DRUG PRODUCTS BY REGION, 2011-2018 ($ MILLIONS) 106
  • FIGURE 27 MARKET SHARE OF SUBSTANCE ABUSE DRUGS BY REGION, 2012 (%) 107
  • FIGURE 28 MARKET REVENUE OF DRUGS USED IN SUBSTANCE AND ALCOHOL ADDICTIONS BY TYPE, 2011-2018 ($ MILLIONS) 110
  • FIGURE 29 MARKET REVENUE FOR SLEEP DISORDER DRUGS BY REGION, 2011-2018 ($ MILLIONS) 112
  • FIGURE 30 MARKET SHARE OF SLEEP DISORDERS THERAPEUTICS BY REGION, 2012 (%) 113
  • FIGURE 31 MARKET REVENUE OF DRUGS USED IN SLEEP DISORDERS BY TYPE, 2011-2018 ($ MILLIONS) 115
  • FIGURE 32 MARKET SHARE OF ANTIDEPRESSANT DRUG MANUFACTURING COMPANIES, 2012 (%) 125
  • FIGURE 33 MARKET SHARE OF ANTIPSYCHOTIC DRUG MANUFACTURING COMPANIES, 2012 (%) 128
  • FIGURE 34 MARKET SHARE OF ANTIANXIETY DRUG MANUFACTURING COMPANIES, 2012 (%) 131
  • FIGURE 35 MARKET SHARE OF CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUG MANUFACTURING COMPANIES, 2012 (%) 134
  • FIGURE 36 MARKET SHARE OF BIPOLAR DISORDER DRUG MANUFACTURING COMPANIES, 2012 (%) 138
  • FIGURE 37 MARKET SHARE OF COGNITIVE DISORDERS DRUG MANUFACTURING COMPANIES, 2012 (%) 140
  • FIGURE 38 MARKET SHARE OF SLEEP DISORDERS DRUG MANUFACTURING COMPANIES, 2012 (%) 143
  • FIGURE 39 MARKET SHARE OF SUBSTANCE ABUSE DRUG MANUFACTURING COMPANIES, 2012 (%) 146
  • FIGURE 40 NUMBER OF SIGNIFICANT PATENTS BY YEAR, JANUARY 2009 TO SEPTEMBER 2013 148
  • FIGURE 41 PATENTS BY CATEGORY, JANUARY 2009 TO SEPTEMBER 2013 150
  • FIGURE 42 PATENT SHARES BY COUNTRY, JANUARY 2009 TO SEPTEMBER 2013 (%) 155
  • FIGURE 43 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009 TO JUNE 2013 155
Back to Top